Sapient Capital LLC Sells 14,000 Shares of Liquidia Corporation $LQDA

Sapient Capital LLC trimmed its holdings in shares of Liquidia Corporation (NASDAQ:LQDA) by 37.8% during the 2nd quarter, Holdings Channel reports. The fund owned 23,000 shares of the company’s stock after selling 14,000 shares during the period. Sapient Capital LLC’s holdings in Liquidia were worth $1,834,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Covestor Ltd raised its holdings in shares of Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after purchasing an additional 359 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Liquidia by 7.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company’s stock valued at $217,000 after purchasing an additional 422 shares in the last quarter. Quantinno Capital Management LP increased its holdings in Liquidia by 3.6% during the first quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock valued at $648,000 after buying an additional 589 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new position in Liquidia during the fourth quarter valued at approximately $25,000. Finally, ProShare Advisors LLC raised its stake in Liquidia by 7.1% in the fourth quarter. ProShare Advisors LLC now owns 11,756 shares of the company’s stock worth $405,000 after buying an additional 775 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: The FDA granted Fast Track designation to YUTREPIA (treprostinil inhalation powder) for systemic sclerosis-associated Raynaud’s phenomenon (SSc-RP). The designation provides more frequent FDA interactions and potentially enables rolling review, Priority Review or Accelerated Approval if applicable. FDA Grants Fast Track Designation to YUTREPIA
• Positive Sentiment: Liquidia plans to begin the approximately 75-patient RE-WARM Phase 2a dose-finding study in October 2026, targeting primary completion in February 2027. SSc-RP affects a substantial population, has no FDA-approved U.S. therapy and represents a potential expansion opportunity for YUTREPIA. Liquidia Gains FDA Fast Track for YUTREPIA
• Positive Sentiment: Coverage highlighted that the YUTREPIA launch is continuing to outperform expectations, supporting the investment case for Liquidia’s commercial execution and revenue growth. YUTREPIA Launch Continues to Outpace Expectations
• Neutral Sentiment: Analysts collectively maintain an average “Hold” rating, indicating that the positive regulatory and commercial developments are balanced by valuation, execution and clinical-development uncertainty. Liquidia Receives Average Hold Rating
• Negative Sentiment: Fast Track is not approval: YUTREPIA’s safety and efficacy for SSc-RP have not been established, and the company must still produce favorable Phase 2a and later-stage data. The indication therefore carries meaningful clinical and regulatory risk. Liquidia Receives FDA Fast Track Designation

Analyst Ratings Changes

A number of analysts have weighed in on LQDA shares. Zacks Research lowered Liquidia from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Wall Street Zen lowered Liquidia from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Bank of America upped their price objective on Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. Oppenheimer set a $75.00 target price on Liquidia in a research note on Friday, June 5th. Finally, Wells Fargo & Company boosted their target price on shares of Liquidia from $62.00 to $108.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $98.08.

Insider Buying and Selling

In other Liquidia news, insider Rajeev Saggar sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $74.06, for a total value of $3,703,000.00. Following the completion of the sale, the insider owned 142,265 shares of the company’s stock, valued at approximately $10,536,145.90. This trade represents a 26.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Katherine Rielly-Gauvin sold 18,393 shares of the business’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $72.23, for a total value of $1,328,526.39. Following the sale, the director owned 44,637 shares in the company, valued at $3,224,130.51. The trade was a 29.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,539,210 shares of company stock valued at $111,412,994 in the last 90 days. 25.60% of the stock is owned by insiders.

Liquidia Price Performance

NASDAQ LQDA opened at $68.66 on Friday. The firm’s fifty day simple moving average is $78.51 and its two-hundred day simple moving average is $58.11. The firm has a market capitalization of $6.15 billion, a P/E ratio of 50.12 and a beta of 0.53. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. Liquidia Corporation has a 12-month low of $21.15 and a 12-month high of $93.61.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). The business had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business’s revenue for the quarter was up 1842.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.49) EPS. Analysts forecast that Liquidia Corporation will post 2.57 EPS for the current fiscal year.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).